Is the use of topical antibiotics for intravitreal injections the standard of care or arewe better offwithout antibiotics?

JAMA Ophthalmology

Volumn 131, Issue 7, 2013, Pages 840-842

  Chen, Royce W S ^a   Rachitskaya, Aleksandra ^a   Scott, Ingrid U ^b,c   Flynn, Harry W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GATIFLOXACIN; MOXIFLOXACIN; POVIDONE IODINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VASCULOTROPIN INHIBITOR;

BACTERIAL LOAD; EDITORIAL; ENDOPHTHALMITIS; HEALTH CARE QUALITY; HUMAN; INFECTIOUS ENDOPHTHALMITIS; INTRAVITREAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 84880290675     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.2524     Document Type: Editorial

References (30)

1. Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina. 2009;29(7): 875-912.
2. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31(4):654-661.
3. Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, et al. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center. Retina. 2011;31(4):662-668.
4. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
5. Irigoyen C, Ziahosseini K, Morphis G, Stappler T, Heimann H. Endophthalmitis following intravitreal injections. Graefes Arch Clin Exp Ophthalmol. 2012;250(4):499-505.
6. Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology. 1991;98(12):1769-1775.
7. Berkelman RL, Holland BW, Anderson RL. Increased bactericidal activity of dilute preparations of povidone-iodine solutions. J Clin Microbiol. 1982;15(4):635-639.
8. Green-Simms AE, Ekdawi NS, Bakri SJ. Survey of intravitreal injection techniques among retinal specialists in the United States. Am J Ophthalmol. 2011;151(2):329-332.
9. Bhavsar AR, Googe JM Jr, Stockdale CR, et al; Diabetic Retinopathy Clinical Research Network. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the Diabetic Retinopathy Clinical Research Network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol. 2009;127(12):1581-1583.
10. Bhavsar AR, Stockdale CR, Ferris FL III, Brucker AJ, Bressler NM, Glassman AR; Diabetic Retinopathy Clinical Research Network. Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. Arch Ophthalmol. 2012;130(6): 809-810.
11. Bhavsar A. Risk of endophthalmitis after intravitreal drug injections with and without use of topical antibiotics in DRCR randomized clinical trials. Paper presented at: Annual Meeting of the American Society of Retina Specialists (ASRS); August 27, 2012; Las Vegas, Nevada.
12. Ta CN, Egbert PR, Singh K, Shriver EM, Blumenkranz MS, Miño De Kaspar H. Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery. Ophthalmology. 2002;109(11):2036- 2040; discussion 2040-2041.
13. Vasavada AR, Gajjar D, Raj SM, Vasavada V, Vasavada V. Comparison of 2moxifloxacin regimens for preoperative prophylaxis: prospective randomized triple-masked trial. part 2: residual conjunctival flora. J Cataract Refract Surg. 2008;34(8):1383-1388.
14. Moss JM, Nguyen D, Liu YI, et al. Comparison of one-day versus one-hour application of topical gatifloxacin in eliminating conjunctival bacterial flora. Ophthalmology. 2008;115(11):2013-2016.
15. Bhatt SS, Stepien KE, Joshi K. Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate. Retina. 2011;31(10): 2032-2036.
16. Moss JM, Sanislo SR, Ta CN. A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections. Ophthalmology. 2009;116(8):1498-1501.
17. Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, LamWC. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012;119(8):1609-1614.
18. Halachmi-Eyal O, Lang Y, Keness Y, Miron D. Preoperative topical moxifloxacin 0. 5%and povidone-iodine 5. 0% versus povidone-iodine 5. 0% alone to reduce bacterial colonization in the conjunctival sac [published correction appears in J Cataract Refract Surg. 2010;36(3):535]. J Cataract Refract Surg. 2009;35(12):2109-2114.
19. Lyall DA, Tey A, Foot B, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye (Lond). 2012;26(12):1517-1526.
20. Mah FS. Fourth-generation fluoroquinolones: new topical agents in thewar on ocular bacterial infections. Curr Opin Ophthalmol. 2004;15(4): 316-320.
21. Morrissey I, Burnett R, Viljoen L, Robbins M. Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002. J Infect. 2004;49(2):109-114.
22. Ta CN, He L, Mino de Kaspar H. In vitro antibiotic susceptibility of preoperative normal conjunctival bacteria. Eye (Lond). 2009;23(3): 559-560.
23. Kim SJ, Toma HS, Midha NK, Cherney EF, Recchia FM, Doherty TJ. Antibiotic resistance of conjunctiva and nasopharynx evaluation study: a prospective study of patients undergoing intravitreal injections. Ophthalmology. 2010;117(12):2372-2378.
24. Schimel AM, Miller D, Flynn HW Jr. Evolving fluoroquinolone resistance among coagulase-negative Staphylococcus isolates causing endophthalmitis. Arch Ophthalmol. 2012;130(12): 1617-1618.
25. Kim SJ, Toma HS. Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections. Ophthalmology. 2011;118(7):1358-1363.
26. Kim SJ, Toma HS. Antimicrobial resistance and ophthalmic antibiotics: 1-year results of a longitudinal controlled study of patients undergoing intravitreal injections. Arch Ophthalmol. 2011;129(9):1180-1188.
27. Milder E, Vander J, Shah C, Garg S. Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection. Ophthalmology. 2012;119(7): 1420-1424.
28. Miño De Kaspar H, Hoepfner AS, EngelbertM, et al. Antibiotic resistance pattern and visual outcome in experimentally-induced Staphylococcus epidermidis endophthalmitis in a rabbit model. Ophthalmology. 2001;108(3):470-478.
29. Miller D, Flynn PM, Scott IU, Alfonso EC, Flynn HW Jr. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol. 2006;124(4):479-483.
30. Schimel AM, Scott IU, Flynn HW Jr. Endophthalmitis after intravitreal injections: should the use of face masks be the standard of care? Arch Ophthalmol. 2011;129(12):1607-1609.